Sanofi steps up with a $645M deal to partner with AstraZeneca on a late-stage RSV antibody
Pointing directly at a pivotal Phase III program, AstraZeneca has decided to partner with Sanofi on an experimental antibody for RSV.
The French pharma giant is paying €120 million upfront and up to €495 million more in development and sales milestones to buy into the program. The two Big Pharmas will now split R&D costs for MEDI8897, with AstraZeneca in charge of manufacturing and Sanofi Pasteur taking control of the commercialization work — provided it goes through to an approval.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.